Who are Apatinib Mesylate, Gefitinib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inlyta, Icotinib plus WBRT, Lenvatinib + losartan, Nilotinib 300 mg., Letybo®, Erlotinib, Pemetrexed.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apatinib-mesylate-gefitinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Apatinib Mesylate, Gefitinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib Mesylate, Gefitinib (Apatinib Mesylate, Gefitinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 1 Tyrosine kinase inhibitor VEGFR-2 and c-KIT Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Apatinib Mesylate, Gefitinib (Apatinib Mesylate, Gefitinib) — Jiangsu HengRui Medicine Co., Ltd.. Tyrosine kinase inhibitor of VEGFR-2 and c-KIT

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Apatinib Mesylate, Gefitinib TARGET	Apatinib Mesylate, Gefitinib	Jiangsu HengRui Medicine Co., Ltd.	phase 1	Tyrosine kinase inhibitor	VEGFR-2 and c-KIT
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Icotinib plus WBRT	Icotinib plus WBRT	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
Lenvatinib + losartan	Lenvatinib + losartan	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist	FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
Nilotinib 300 mg.	Nilotinib 300 mg.	King Abdullah International Medical Research Center	marketed	BCR-ABL tyrosine kinase inhibitor	BCR-ABL
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apatinib Mesylate, Gefitinib — Competitive Intelligence Brief. https://druglandscape.com/ci/apatinib-mesylate-gefitinib. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab